|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
56,030,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Kronos Bio is a late-stage clinical development biopharmaceutical company, with a focus on developing therapeutics that target the dysregulated transcription that causes cancer and other serious diseases. Co.'s primary product candidate, entospletinib, is an orally administered, selective spleen tyrosine kinase (SYK) inhibitor. Co. is also developing lanraplenib, its orally-administered SYK inhibitor. In addition, Co. is developing KB-0742, its internally discovered, oral cyclin dependent kinase 9 inhibitor, for the treatment of MYC-amplified and other transcriptionally addicted solid tumors.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
204,670 |
5,351,696 |
| Total Buy Value |
$0 |
$0 |
$254,957 |
$5,323,275 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
8 |
| Total Shares Sold |
24,838 |
24,838 |
24,838 |
140,866 |
| Total Sell Value |
$21,554 |
$21,554 |
$21,554 |
$173,518 |
| Total People Sold |
1 |
1 |
1 |
8 |
| Total Sell Transactions |
1 |
1 |
1 |
12 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bischofberger Norbert W |
|
– • • |
2025-06-20 |
4 |
D |
$0.57 |
$6,758,569 |
I/I |
(11,857,138) |
0 |
|
- |
|
| Yang Taiyin |
|
– • – |
2025-06-20 |
4 |
D |
$0.57 |
$6,460 |
D/D |
(11,333) |
0 |
|
- |
|
| Ridloff Elena |
|
– • – |
2025-06-20 |
4 |
D |
$0.57 |
$14,419 |
D/D |
(25,296) |
0 |
|
- |
|
| Belldegrun Arie |
|
– • – |
2025-06-20 |
4 |
D |
$0.57 |
$1,963,587 |
I/I |
(3,444,889) |
0 |
|
- |
|
| Knobelman Deborah |
President & Interim CEO |
• – – |
2025-06-20 |
4 |
D |
$0.57 |
$79,471 |
D/D |
(139,422) |
0 |
|
- |
|
| Tanen David M |
|
– • – |
2025-06-20 |
4 |
D |
$0.57 |
$313,702 |
I/I |
(550,355) |
0 |
|
- |
|
| Tanen David M |
|
– • – |
2025-06-20 |
4 |
D |
$0.57 |
$207,154 |
D/D |
(363,428) |
0 |
|
- |
|
| Kazam Joshoa A |
|
– • – |
2025-06-20 |
4 |
D |
$0.57 |
$53,854 |
D/D |
(94,481) |
0 |
|
- |
|
| Knobelman Deborah |
President & Interim CEO |
• – – |
2025-06-05 |
4 |
S |
$0.87 |
$21,554 |
D/D |
(24,838) |
139,422 |
|
- |
|
| Bischofberger Norbert W |
PRESIDENT & CEO |
• • – |
2024-06-28 |
4 |
B |
$1.25 |
$254,957 |
I/I |
204,670 |
10,802,138 |
0.01 |
- |
|
| Bischofberger Norbert W |
PRESIDENT & CEO |
• • – |
2024-06-27 |
4 |
B |
$1.17 |
$478,843 |
I/I |
410,848 |
10,597,468 |
0.01 |
- |
|
| Ridloff Elena |
|
– • – |
2024-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
11,333 |
25,296 |
|
- |
|
| Bischofberger Norbert W |
PRESIDENT & CEO |
• • – |
2024-06-12 |
4 |
B |
$1.24 |
$1,096,041 |
I/I |
881,913 |
7,375,616 |
0.01 |
- |
|
| Bischofberger Norbert W |
PRESIDENT & CEO |
• • – |
2024-06-11 |
4 |
B |
$1.09 |
$814,571 |
I/I |
744,308 |
6,493,703 |
0.01 |
- |
|
| Bischofberger Norbert W |
PRESIDENT & CEO |
• • – |
2024-06-10 |
4 |
B |
$0.88 |
$1,208,469 |
I/I |
1,378,901 |
5,749,395 |
0.01 |
- |
|
| Knobelman Deborah |
Chief Financial Officer |
• – – |
2024-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
164,260 |
164,260 |
|
- |
|
| Olek Elizabeth A |
SR VP, CLINICAL SCIENCE |
• – – |
2024-02-21 |
4 |
S |
$1.05 |
$7,765 |
D/D |
(7,368) |
193,275 |
|
- |
|
| Frisbee Allison |
SR VP, CORP OPERATIONS & LEGAL |
• – – |
2024-02-21 |
4 |
S |
$1.05 |
$12,757 |
D/D |
(12,105) |
204,510 |
|
- |
|
| Lin Charles Y |
SR VP, RESEARCH & DEVELOPMENT |
• – – |
2024-02-21 |
4 |
S |
$1.05 |
$12,685 |
D/D |
(12,036) |
234,603 |
|
- |
|
| Bischofberger Norbert W |
PRESIDENT & CEO |
• • – |
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
270,339 |
2,811,004 |
|
- |
|
| Dinsmore Christopher |
Chief Scientific Officer |
• – – |
2024-01-04 |
4 |
S |
$1.18 |
$8,718 |
D/D |
(7,366) |
260,969 |
|
- |
|
| Dimartino Jorge |
Chief Medical Officer & VP |
• – – |
2024-01-04 |
4 |
S |
$1.18 |
$14,214 |
D/D |
(12,009) |
315,246 |
|
- |
|
| Kosacz Barbara |
COO & General Counsel |
• – – |
2024-01-04 |
4 |
S |
$1.18 |
$12,636 |
D/D |
(10,676) |
928,966 |
|
- |
|
| Dimartino Jorge |
Chief Medical Officer & VP |
• – – |
2023-12-12 |
4 |
S |
$1.31 |
$22,664 |
D/D |
(17,367) |
327,255 |
|
- |
|
| Dinsmore Christopher |
Chief Scientific Officer |
• – – |
2023-12-12 |
4 |
S |
$1.31 |
$13,092 |
D/D |
(10,032) |
268,335 |
|
- |
|
113 Records found
|
|
Page 1 of 5 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
